Skip to main content

About Us

Who we are

The Agency for Care Effectiveness (ACE) is the national health technology assessment (HTA) agency in Singapore, established by the Ministry of Health in 2015 to drive better decision-making about clinically effective and cost-effective patient care.


"The current challenging economic outlook is a timely reminder of the need to ensure sustainability, not just for ourselves but for future generations…. Therefore, we need to choose care that is appropriate to needs, so that we can make the best use of our limited resources.

Emerging healthcare technologies are becoming increasingly expensive and we need to ensure that the outcomes derived from these technologies are commensurate with these costs… recently set up the Agency for Care Effectiveness… to expand our capacity in evaluating the clinical and cost effectiveness of health technologies… and develop guidance to… help patients, caregivers and physicians make more informed decisions on treatments..."

Extract from Speech by Mr Gan Kim Yong, Minister for Health at MOH Committee of Supply Debate 2016.

Our vision

To improve patient outcomes and healthcare value through health technology assessment

Our mission

To issue objective and credible healthcare guidance
To enable stakeholders to optimize health benefits within finite resources
To advance the values of evidence-based practice and appropriate care

Our core values

Scientific Excellence. Collaboration. Impacting Lives.

What we do

Advancements in medicine and the development of new health technologies offer the potential for improved healthcare in Singapore. However, some technologies, while costing more, may not offer significant advantages for patients. ACE aims to support policy-makers, clinicians and patients to make better decisions through health technology assessment (HTA).

ACE systematically evaluates health technologies, such as drugs, devices and medical services, using established HTA methods which take into account expert opinion and scientific evidence. The evaluations compare health technologies with alternative treatment options to identity interventions that are clinically effective and offer the best value for patients.

These evaluations equip policy makers with objective and credible evidence to guide subsidy decisions on healthcare treatments. In addition, ACE’s work will help healthcare institutions, doctors and patients in Singapore make better informed decisions on tests and treatments appropriate for their conditions.

From May 2017 onwards, ACE will be publishing guidances, which outline recommendations on the appropriate use of the health technologies evaluated, provide a brief summary of the rationale for the subsidy decision, as well as the key clinical and economic evidence which informed the recommendations. The publication of guidances increase the level of transparency of decision-making, and is consistent with how subsidy decisions are communicated by other HTA agencies internationally. ACE will also be publishing 'Appropriate Care Guides', which are concise sets of recommended care practices and pathways aimed at improving selected areas of therapy.

Our logo

Our logo depicts the three core groups of stakeholders — policy makers, clinicians and patients — working closely with us to achieve our mission of driving informed, impartial and sound decision-making in healthcare. The intertwining figures symbolise the synergistic efforts of the Agency and our stakeholders in improving patient outcomes while keeping healthcare affordable for all.

Our organisation structure

The Agency for Care Effectiveness is a part of the Ministry of Health with an advisory council appointed by the Minister to steer the Agency’s long term development.

The Agency is led by our executive director, Dr Daphne Khoo, with two main branches, the evaluation branch headed by Mr Ng Kwong Hoe; and the planning and policy branch, headed by Ms Elaine Teo.

The evaluation branch conducts health technology assessments and develops guidance for drugs, devices and medical services, as well as appropriate care guides. They are also the secretariat for the relevant advisory committees in MOH.

The planning and policy branch manages corporate planning and administration, local and international collaborations for the Agency’s development, and is the secretariat to ACE's council. The branch also manages the engagement with policy divisions in the Ministry and external stakeholders to facilitate the adoption of ACE's guidances.

Committees that we serve

ACE Council

The ACE Council was formed as an advisory body to steer the Agency's development to drive appropriate healthcare in Singapore. Led by an eminent senior clinician, the Council comprises well-respected senior medical specialists and professionals across a range of disciplines.

The combined expertise and experience of Council members in medicine, research and academia, health economics, legal, social policy and government policy, present a holistic perspective to guide the Agency's development.

The Council’s terms of reference:

  1. Act as ambassadors to promote the values of evidence-based practice and appropriate care.
  2. Ensure that the Agency's strategic objectives, business plans, activities and outputs to guide effective clinical care are appropriate to Singaporeans' needs.
  3. Advise MOH and the Agency's executive team on strategic, implementation, performance and communication issues.
  4. Guide collaborations and facilitate the development of networks and relationships with key stakeholders to support the development and/or implementation of ACE's guidances and programmes.

MOH Drug Advisory Committee

The MOH Drug Advisory Committee (DAC) is responsible for providing evidence-based recommendations to MOH so that decisions for public funding of drugs are made in a fair, efficient and sustainable manner.

The DAC’s terms of reference:

  1. To prioritise drug applications which hold potential for driving significant improvement in health outcomes;
  2. To appraise the effectiveness of drugs based on specific therapeutic, clinical and pharmacoeconomic evidence; and
  3. To provide drug listing recommendations to the Ministry of Health, including conditions and/or criteria for subsidy.

Last updated on 3 May 2017 Back to Top